Liposomes as Potential Drug Carrier Systems for Drug Delivery
暂无分享,去创建一个
[1] N. Ostrowsky. Liposome size measurements by photon correlation spectroscopy , 1993 .
[2] M. Bally,et al. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. , 1990, Biochimica et biophysica acta.
[3] Q. Ping,et al. Lecithin vesicular carriers for transdermal delivery of cyclosporin A. , 2000, International journal of pharmaceutics.
[4] H. Miura,et al. Improvement of encapsulation efficiency of water-soluble drugs in liposomes formed by the freeze-thawing method. , 1985, Chemical & pharmaceutical bulletin.
[5] Joel Fried,et al. Polymer Science and Technology , 1995 .
[6] A. Ludwig,et al. The use of mucoadhesive polymers in ocular drug delivery. , 2005, Advanced drug delivery reviews.
[7] R. Müller,et al. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization , 1994 .
[8] S. Balasubramanian,et al. Preparation and characterization of taxane-containing liposomes. , 2005, Methods in enzymology.
[9] T. Lodge,et al. Temperature dependence of dynamic light scattering in the intermediate momentum transfer region , 1983 .
[10] D. Engelman,et al. Bilayer interactions of pHLIP, a peptide that can deliver drugs and target tumors. , 2008, Biophysical journal.
[11] Ming-Ren Toh,et al. Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing , 2013 .
[12] G. Patel,et al. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. , 1999, Critical reviews in biotechnology.
[13] D. Hinton,et al. Simultaneous measurement of vesicle diffusion coefficients and trapping efficiencies by means of diffusion ordered 2D NMR spectroscopy. , 1994, Chemistry and physics of lipids.
[14] P. Cullis,et al. Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. , 1999, Biochimica et biophysica acta.
[15] C. Alving,et al. Complement-Dependent Phagocytosis of Liposomes: Suppression by “Stealth” Lipids , 1992 .
[16] V. Torchilin,et al. Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo , 1991, FEBS letters.
[17] S. Jain,et al. Ethosomes : A Novel Vesicular Carrier For Enhanced Transdermal Delivery Of An AntiHIV Agent , 2004 .
[18] E. Korn,et al. Single bilayer liposomes prepared without sonication. , 1973, Biochimica et biophysica acta.
[19] W. Lorenz,et al. Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent , 1977, Agents and Actions.
[20] Jian Chen,et al. Investigation of archaeosomes as carriers for oral delivery of peptides. , 2010, Biochemical and biophysical research communications.
[21] I. Kellaway,et al. Poloxamer sorption on liposomes: comparison with polystyrene latex and influence on solute efflux , 1988 .
[22] B. Rouse,et al. Target-sensitive immunoliposomes: preparation and characterization. , 1986, Biochemistry.
[23] T. Anchordoquy,et al. Maintenance of transfection rates and physical characterization of lipid/DNA complexes after freeze-drying and rehydration. , 1997, Archives of biochemistry and biophysics.
[24] R. W. Baldwin,et al. Adsorption of monoclonal antibodies to polyhexylcyanoacrylate nanoparticles and subsequent immunospecific binding to tumour cells in vitro , 1983 .
[25] Rakesh K. Sharma,et al. Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice , 2006, The AAPS Journal.
[26] Manuel Alatorre-Meda,et al. DNA-METAFECTENE PRO complexation: a physical chemistry study. , 2010, Physical chemistry chemical physics : PCCP.
[27] Y. Rustum,et al. Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles. , 1976, Cancer research.
[28] T. Dutta,et al. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[29] T. Anchordoquy,et al. Maintenance of nonviral vector particle size during the freezing step of the lyophilization process is insufficient for preservation of activity: insight from other structural indicators. , 2001, Journal of pharmaceutical sciences.
[30] U. Pick,et al. Liposomes with a large trapping capacity prepared by freezing and thawing of sonicated phospholipid mixtures. , 1981, Archives of biochemistry and biophysics.
[31] S. Tsukagoshi,et al. Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210. , 1975, Gan.
[32] F. Dosio,et al. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[33] J. Wilschut,et al. Delivery of Protein Antigens to the Immune System by Fusion-Active Virosomes: A Comparison with Liposomes and ISCOMs , 2002, Bioscience reports.
[34] B. Godin,et al. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[35] S. Feng,et al. Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel. , 2003, Biomaterials.
[36] Massimo Fresta,et al. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[37] K. Hande,et al. Etoposide: four decades of development of a topoisomerase II inhibitor. , 1998, European journal of cancer.
[38] J. Hadgraft,et al. Evaluation of Mucoadhesive Polymers in Ocular Drug Delivery. II. Polymer-Coated Vesicles , 1992, Pharmaceutical Research.
[39] Vladimir P Torchilin,et al. Nanopreparations for organelle-specific delivery in cancer. , 2014, Advanced drug delivery reviews.
[40] Kazuo Maruyama,et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.
[41] G. Gahrton,et al. Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation. , 1983, Advances in cancer research.
[42] Y. Kaneda,et al. Virosomes: evolution of the liposome as a targeted drug delivery system. , 2000, Advanced drug delivery reviews.
[43] M. Hope,et al. Antibacterial Efficacy against an In Vivo Salmonella typhimurium Infection Model and Pharmacokinetics of a Liposomal Ciprofloxacin Formulation , 1998, Antimicrobial Agents and Chemotherapy.
[44] V. Torchilin,et al. Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. , 1994, Biochimica et biophysica acta.
[45] D. Crommelin,et al. The preparation of tissue-type Plasminogen Activator (t-PA) containing liposomes: entrapment efficiency and ultracentrifugation damage. , 1995, Journal of drug targeting.
[46] C. Ehrhardt,et al. Inhaled Liposomes–Current Strategies and Future Challenges , 2008 .
[47] A A Bogdanov,et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. , 1994, Biochimica et biophysica acta.
[48] M. T. ten Kate,et al. Improved Efficacy of Ciprofloxacin Administered in Polyethylene Glycol-Coated Liposomes for Treatment of Klebsiella pneumoniae Pneumonia in Rats , 2001, Antimicrobial Agents and Chemotherapy.
[49] S. Vyas,et al. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis , 2007, Journal of drug targeting.
[50] V. Usonis,et al. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). , 2003, Vaccine.
[51] J. Watkins,et al. Suspected anaphylactic reaction to Cremophor EL. , 1980, British medical journal.
[52] José Villalaín,et al. Influence of liposome charge and composition on their interaction with human blood serum proteins , 1993, Molecular and Cellular Biochemistry.
[53] D. Papahadjopoulos,et al. Medical applications of liposomes , 1998 .
[54] D. Kingston,et al. Design, synthesis, and bioactivities of steroid-linked taxol analogues as potential targeted drugs for prostate and breast cancer. , 2004, Journal of natural products.
[55] S. A. Kramer,et al. Effect of povidone-iodine on wound healing: a review. , 1999, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.
[56] J. Wilschut,et al. Influenza virosomes in vaccine development. , 2003, Methods in enzymology.
[57] G. Cevc. Drug-Carrier and Stability Properties of the Long-Lived Lipid Vesicles. Cryptosomes, in Vitro and in Vivo , 1992 .
[58] P. Cullis,et al. Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study. , 1998, Biochimica et biophysica acta.
[59] J. Huwyler,et al. Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[60] J. Rogers,et al. Polymer-coated liposomes; stability and release of ASA from carboxymethyl chitin-coated liposomes , 1991 .
[61] Adrian C. Williams,et al. Transdermal and Topical Drug Delivery : From Theory to Clinical Practice , 2003 .
[62] D. Lasič,et al. Doxorubicin in sterically stabilized liposomes , 1996, Nature.
[63] J. Reuben,et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. , 1985, The Journal of infectious diseases.
[64] R. Straubinger,et al. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. , 1993, Cancer research.
[65] R. New,et al. Liposomes : a practical approach , 1990 .
[66] N. Bressler. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.
[67] V. Torchilin. Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.
[68] G Gregoriadis,et al. Drug entrapment in liposomes , 1973, FEBS letters.
[69] E. Eliav,et al. A clinical evaluation of a novel liposomal carrier for acyclovir in the topical treatment of recurrent herpes labialis. , 1999, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[70] S. Balasubramanian,et al. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. , 1995, Journal of pharmaceutical sciences.
[71] J. S. Dua,et al. LIPOSOME: METHODS OF PREPARATION AND APPLICATIONS , 2012 .
[72] A. Gabizon,et al. The role of surface charge and hydrophilic groups on liposome clearance in vivo. , 1992, Biochimica et biophysica acta.
[73] J. Hubbell,et al. Solution technique to incorporate polyethylene oxide and other water-soluble polymers into surfaces of polymeric biomaterials. , 1991, Biomaterials.
[74] P I Campbell,et al. Toxicity of some charged lipids used in liposome preparations. , 1983, Cytobios.
[75] F. Szoka,et al. Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. , 1980, Biochimica et biophysica acta.
[76] G Gregoriadis,et al. The carrier potential of liposomes in biology and medicine (second of two parts). , 1976, The New England journal of medicine.
[77] D. Lasič. Novel applications of liposomes. , 1998, Trends in biotechnology.
[78] P. Bharat,et al. A COMPLETE REVIEW ON : LIPOSOMES , 2012 .
[79] N. Van Rooijen,et al. Liposomes in immunology: multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own. , 1980, Immunological communications.
[80] J. Puskin,et al. A spin label method for measuring internal volumes in liposomes or cells, applied to Ca-dependent fusion of negatively charged vesicles. , 1981, Biochimica et biophysica acta.
[81] D. Lasič,et al. Liposomes: From Physics to Applications , 1993 .
[82] Amarnath Sharma,et al. Liposomes in drug delivery: Progress and limitations , 1997 .
[83] Joseph A. Zasadzinski,et al. Nanocompartments Enclosing Vesicles, Colloids, and Macromolecules via Interdigitated Lipid Bilayers , 2002 .
[84] M. Woodle,et al. Sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.
[85] J. Viret,et al. Virosomal adjuvanted antigen delivery systems , 2003, Expert review of vaccines.
[86] L. Mayer,et al. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. , 2001, The Journal of pharmacology and experimental therapeutics.
[87] F. Levi-Schaffer,et al. Intracellular delivery mediated by an ethosomal carrier. , 2001, Biomaterials.
[88] M. Bally,et al. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. , 1985, Biochimica et biophysica acta.
[89] J. Patton. Inhalation delivery of therapeutic peptides and proteins. , 1999, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[90] Yingjin Yuan,et al. Synthesis and evaluation of water-soluble paclitaxel prodrugs. , 2002, Bioorganic & medicinal chemistry letters.
[91] P. Rougé,et al. Modes of membrane interaction of a natural cysteine-rich peptide: viscotoxin A3. , 2002, Biochimica et biophysica acta.
[92] Y. Barenholz,et al. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. , 1989, European journal of cancer & clinical oncology.
[93] R. Donehower,et al. Drug therapy : paclitaxel (Taxol) , 1995 .
[94] P. Lambelet,et al. The fate of antioxidant radicals during lipid autooxidation. I. The tocopheroxyl radicals. , 1984, Chemistry and physics of lipids.
[95] Mayank M. Patel,et al. The stability of lyophilized lipid/DNA complexes during prolonged storage. , 2004, Journal of pharmaceutical sciences.
[96] D. Needham,et al. The "Stealth" Liposome: A Prototypical Biomaterial , 1995 .
[97] M. Nakano,et al. Clinical Pharmacokinetics of Cytarabine Formulations , 2002, Clinical pharmacokinetics.
[98] A. R. Fernandes,et al. Application of Nanotechnology in Drug Delivery , 2014 .
[99] G. Betageri,et al. Factors affecting microencapsulation of drugs in liposomes. , 1995, Journal of microencapsulation.
[100] F. Szoka,et al. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. , 1979, Biochimica et biophysica acta.
[101] Zhuo Georgia Chen,et al. Advances of cancer therapy by nanotechnology. , 2009, Cancer research and treatment : official journal of Korean Cancer Association.
[102] G. Gregoriadis,et al. Liposomes and cancer therapy. , 1991, Cancer cells.
[103] F. Frézard,et al. Liposomes: from biophysics to the design of peptide vaccines. , 1999, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[104] P. Beaumier,et al. Effects of liposome size on the degradation of bovine brain sphingomyelin/cholesterol liposomes in the mouse liver. , 1983, Biochimica et biophysica acta.
[105] D. P. Sarkar,et al. Targeted gene delivery by virosomes. , 2002, Methods in molecular biology.
[106] J. Zasadzinski,et al. Encapsulating vesicles and colloids from cochleate cylinders , 2003 .
[107] F. Martin,et al. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipid , 1992, International journal of cancer.
[108] J. Akbuǧa,et al. Encapsulation of Enrofloxacin in Liposomes I: Preparation and In Vitro Characterization of LUV , 2004, Journal of liposome research.
[109] R. Fielding. Liposomal Drug Delivery , 1991, Clinical pharmacokinetics.
[110] G. Patel,et al. In vitro assessment of archaeosome stability for developing oral delivery systems. , 2000, International journal of pharmaceutics.
[111] S. Kawakami,et al. Prednisolone retention in integrated liposomes by chemical approach and pharmaceutical approach. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[112] L. Packer,et al. [89] Measurements of volumes and electrochemical gradients with spin probes in membrane vesicles , 1982 .
[113] B. W. Barry,et al. Novel mechanisms and devices to enable successful transdermal drug delivery. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[114] J. D. de Pablo,et al. Effect of sugar-phosphate mixtures on the stability of DPPC membranes in dehydrated systems. , 2004, Cryobiology.
[115] J. Fendler,et al. Liposomes as drug carriers. , 1977, Life sciences.
[116] A. Driessen,et al. The stability and functional properties of proteoliposomes mixed with dextran derivatives bearing hydrophobic anchor groups. , 1992, Biochimica et biophysica acta.
[117] D. Wallach,et al. Some properties of N-acyl sarcosinate lipid vesicles , 1992 .
[118] A. El‐Kattan,et al. Enhancement of transdermal drug delivery: chemical and physical approaches. , 2000, Critical reviews in therapeutic drug carrier systems.
[119] L. Mayer,et al. Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. , 1985, Biochimica et biophysica acta.
[120] Agustina Gómez-Hens,et al. Analytical methods for the control of liposomal delivery systems , 2006 .
[121] M. Malmsten,et al. Effect of lipid headgroup composition on the interaction between melittin and lipid bilayers. , 2007, Journal of colloid and interface science.
[122] R. Devraj,et al. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. , 2002, Journal of colloid and interface science.
[123] A. Misra,et al. Ethosomes: a novel delivery system for antifungal drugs in the treatment of topical fungal diseases. , 2009, Indian journal of experimental biology.
[124] G Blume,et al. Molecular mechanism of the lipid vesicle longevity in vivo. , 1993, Biochimica et biophysica acta.
[125] M. Hashida,et al. An application of water-in-oil and gelatin-microsphere-in-oil emulsions to specific delivery of anticancer agent into stomach lymphatics , 1977, Journal of Pharmacokinetics and Biopharmaceutics.
[126] K. Behar,et al. Determination of liposomal encapsulation efficiency using proton NMR spectroscopy. , 2004, Chemistry and physics of lipids.
[127] N. Weiner,et al. The influence of lipid composition and lamellarity of liposomes on the physical stability of liposomes upon storage , 1996 .
[128] G. Sprott. Structures of archaebacterial membrane lipids , 1992, Journal of bioenergetics and biomembranes.
[129] K. Katayama,et al. Improved Drug Delivery to Target Specific Organs Using Liposomes as Coated with Polysaccharides , 1983 .
[130] D. Arifin,et al. Determination of Size Distribution and Encapsulation Efficiency of Liposome‐Encapsulated Hemoglobin Blood Substitutes Using Asymmetric Flow Field‐Flow Fractionation Coupled with Multi‐Angle Static Light Scattering , 2003, Biotechnology progress.
[131] Simon C Watkins,et al. Lyophilization of cationic lipid-protamine-DNA (LPD) complexes. , 2000, Journal of pharmaceutical sciences.
[132] Y. Mizushima,et al. Use of a lipid emulsion as a novel carrier for corticosteroids , 1982, The Journal of pharmacy and pharmacology.
[133] A. Manosroi,et al. Characterization of Amphotericin B Liposome Formulations , 2004, Drug development and industrial pharmacy.
[134] F. Dehghani,et al. Conventional and Dense Gas Techniques for the Production of Liposomes: A Review , 2008, AAPS PharmSciTech.
[135] T. Yonetani,et al. Preparation and characterization of liposome-encapsulated haemoglobin by a freeze-thaw method. , 1994, Journal of microencapsulation.
[136] D. Deamer,et al. Large volume liposomes by an ether vaporization method. , 1976, Biochimica et biophysica acta.
[137] V. Torchilin,et al. Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[138] G. Feigenson,et al. A novel strategy for the preparation of liposomes: rapid solvent exchange. , 1999, Biochimica et biophysica acta.
[139] J. Neuzil,et al. Lyophilised liposome-based formulations of alpha-tocopheryl succinate: preparation and physico-chemical characterisation. , 2010, Journal of pharmaceutical sciences.
[140] G. Gregoriadis,et al. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. , 1980, The Biochemical journal.
[141] R. Macdonald,et al. A simple procedure for the determination of the trapped volume of liposomes , 1982 .
[142] I. Ahmad,et al. Determination by liquid chromatography with fluorescence detection of total 7-ethyl-10-hydroxy-camptothecin (SN-38) in beagle dog plasma after intravenous administration of liposome-based SN-38 (LE-SN38). , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[143] R. Singh,et al. Recent advances in various emerging vescicular systems: An overview , 2012 .
[144] E. Fattal,et al. Use of an enzyme immunoassay for the evaluation of entrapment efficiency and in vitro stability in intestinal fluids of liposomal bovine serum albumin , 1996 .
[145] Rapid method for determination of residual tert-butanol in liposomes using solid-phase microextraction and gas chromatography. , 2010, Journal of chromatographic science.
[146] J. Giddings,et al. Size distribution of liposomes by flow field-flow fractionation. , 1993, Journal of pharmaceutical and biomedical analysis.
[147] T. Allen,et al. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. , 1992, Cancer research.
[148] Henk-Jan Guchelaar,et al. Liposomal drug formulations in cancer therapy: 15 years along the road. , 2012, Drug discovery today.
[149] D. Deamer. PREPARATION AND PROPERTIES OF ETHER‐INJECTION LIPOSOMES * , 1978, Annals of the New York Academy of Sciences.
[150] P. Caliceti,et al. New synthetic amphiphilic polymers for steric protection of liposomes in vivo. , 1995, Journal of pharmaceutical sciences.
[151] A. Janoff,et al. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts , 1997, International journal of cancer.
[152] R. Biltonen,et al. The use of differential scanning calorimetry as a tool to characterize liposome preparations , 1993 .
[153] G. Smolin,et al. Idoxuridine-liposome therapy for herpes simplex keratitis. , 1981, American journal of ophthalmology.
[154] G. Hortobagyi,et al. Risks and Benefits of Taxanes in Breast and Ovarian Cancer , 2000, Drug safety.
[155] J. Barbeau,et al. Archaeal tetraether bipolar lipids: Structures, functions and applications. , 2009, Biochimie.
[156] K. Maruyama,et al. Effect of molecular weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes. , 1991, Chemical & pharmaceutical bulletin.
[157] K. Gelmon,et al. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection , 1998, Cancer Chemotherapy and Pharmacology.
[158] G Gregoriadis,et al. Engineering liposomes for drug delivery: progress and problems. , 1995, Trends in biotechnology.
[159] I. Kwon,et al. Polymeric micelles of poly(2-ethyl-2-oxazoline)-block-poly(ε-caprolactone) copolymer as a carrier for paclitaxel , 2003 .
[160] Patel Gb,et al. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. , 1999 .
[161] Q. Xu,et al. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 degrees C. , 1994, American journal of hospital pharmacy.
[162] K. Wasan,et al. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[163] J. Mascola,et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. , 1998, Journal of immunology.
[164] G. Storm,et al. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. , 1993, Biochimica et biophysica acta.
[165] J. Sunamoto,et al. Bile salt damage of egg phosphatidylcholine liposomes. , 1985, Biochimica et biophysica acta.
[166] Patrick Couvreur,et al. Pharmacokinetics and Distribution of a Biodegradable Drug-carrier , 1983 .
[167] W. Richter,et al. Synthetic glycolipids as membrane-bound cryoprotectants in the freezedrying process of liposomes , 1996 .
[168] M. Schofield,et al. Cholesterol versus cholesterol sulfate: effects on properties of phospholipid bilayers containing docosahexaenoic acid. , 1998, Chemistry and physics of lipids.
[169] Jonathan D. Ashley,et al. Ligand-targeted liposome design: challenges and fundamental considerations. , 2014, Trends in biotechnology.
[170] B. Leyland-Jones,et al. Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[171] V. Labhasetwar,et al. A study on zeta potential and dielectric constant of liposomes. , 1994, Journal of microencapsulation.
[172] M. S. Muthu,et al. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. , 2009, Nanomedicine.
[173] Sanyog Jain,et al. Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver , 2006, The Journal of pharmacy and pharmacology.
[174] Vladimir P. Torchilin,et al. Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents , 1995 .
[175] S. Vyas,et al. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting , 2007, Journal of drug targeting.
[176] K. P. Rao,et al. Studies on the carboxymethyl chitosan-containing liposomes for their stability and controlled release of dapsone. , 1991, Journal of microencapsulation.
[177] B. Godin,et al. Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[178] T. Allen,et al. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.
[179] Sérgio Simões,et al. On the formulation of pH-sensitive liposomes with long circulation times. , 2004, Advanced drug delivery reviews.
[180] Hesson Chung,et al. Polymeric micelles of poly(2-ethyl-2-oxazoline)-block-poly(epsilon-caprolactone) copolymer as a carrier for paclitaxel. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[181] C. Rhodes,et al. Preparation and characterization of liposomes as therapeutic delivery systems: a review. , 1995, Pharmaceutica acta Helvetiae.
[182] G. Gregoriadis. Overview of liposomes. , 1991, The Journal of antimicrobial chemotherapy.
[183] V. H. Lee,et al. Ocular drug bioavailability from topically applied liposomes. , 1985, Survey of ophthalmology.
[184] R. Glück,et al. Influenza virosomes as an efficient system for adjuvanted vaccine delivery , 2004, Expert opinion on biological therapy.
[185] M. Woodle,et al. Controlling liposome blood clearance by surface-grafted polymers. , 1998, Advanced drug delivery reviews.
[186] Neil M Bressler,et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.
[187] J. M. Shaw,et al. Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs , 1996, Pharmaceutical Research.
[188] T M Allen,et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.
[189] V. Torchilin,et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. , 2001, Biochimica et biophysica acta.
[190] A. Gabizon,et al. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[191] Ulrich Beyer,et al. Liposomal encapsulated anti-cancer drugs. , 2005, Anti-cancer drugs.
[192] G. Gregoriadis,et al. Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. , 1971, The Biochemical journal.
[193] M. Bally,et al. Uptake of dibucaine into large unilamellar vesicles in response to a membrane potential. , 1985, The Journal of biological chemistry.
[194] A. McPhail,et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.
[195] M. Stuart,et al. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. , 1995, Biochimica et biophysica acta.
[196] C. Pi. Toxicity of some charged lipids used in liposome preparations. , 1983 .
[197] C Huang,et al. Studies on phosphatidylcholine vesicles. Formation and physical characteristics. , 1969, Biochemistry.
[198] M. R. Mozafari,et al. Nanoliposomes and their applications in food nanotechnology. , 2008, Journal of liposome research.
[199] V. Torchilin,et al. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. , 1991, Biochimica et biophysica acta.
[200] A. Bangham,et al. Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.
[201] S. L. Kumar,et al. EMULSOMES: AN EMERGING VESICULAR DRUG DELIVERY SYSTEM , 2013 .
[202] C. Herzog,et al. Virosome influenza vaccine in children. , 2002, Vaccine.
[203] Yechezkel Barenholz,et al. Liposome application: problems and prospects , 2001 .
[204] S. Clerc,et al. Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. , 1995, Biochimica et biophysica acta.
[205] Ching-Hsien Huang,et al. Phosphatidylcholine vesicles. Formation and physical characteristics , 1969 .
[206] P. Correale,et al. Efficient delivery of DNA to dendritic cells mediated by influenza virosomes. , 2004, Vaccine.
[207] M. Bally,et al. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes , 1997, Cancer Chemotherapy and Pharmacology.
[208] N. Rooijen,et al. Liposomes in immunology: multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own. , 1980 .
[209] N. Mishra,et al. Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. , 2009, International journal of pharmaceutics.
[210] V. Kochupillai,et al. Encapsulation in Cationic Liposomes Enhances Antitumour Efficacy and Reduces the Toxicity of Etoposide, a Topo-Isomerase II Inhibitor , 2001, Pharmacology.
[211] G. Gregoriadis. The Carrier Potential of Liposomes in Biology and Medicine , 1976 .
[212] P. Artursson,et al. Preparation and evaluation of sterically stabilized liposomes: colloidal stability, serum stability, macrophage uptake, and toxicity. , 1990, Journal of pharmaceutical sciences.
[213] A. Florence,et al. Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. , 1993, Drugs.
[214] D. Needham,et al. The “Stealth” Liposome: A Prototypical Biomaterial , 1996 .
[215] O. Katare,et al. Topical treatment in vitiligo and the potential uses of new drug delivery systems. , 2010, Indian journal of dermatology, venereology and leprology.
[216] V. Torchilin,et al. Which polymers can make nanoparticulate drug carriers long-circulating? , 1995 .